Moderna shares were up 13% Friday after the biotech company revealed a new effort to make a treatment for autoimmune ...

The S&P 500 ended marginally lower on Friday, with a steep drop in AI-related chip stocks and sharp gains ​in Moderna and ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in ...

U.S. pharmaceutical company Moderna announced on the 26th (local time) that it will begin developing an “in vivo CAR-T” ...

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Hims & Hers Health (HIMS) stock, Replimune (REPL) stock, and Capricor (CAPR) stock are in focus as the FDA brings back Advisory Committee meetings. Read more here.

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...